The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector.

BACKGROUND AND OBJECTIVE: Malaria is a disease of major public health importance in Kenya killing 26,000 children under 5 years of age annually. This paper seeks to assess the quality of sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) products available over-the-counter to communities in Kenya...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों: Amin, A, Snow, R, Kokwaro, G
स्वरूप: Journal article
भाषा:English
प्रकाशित: 2005
_version_ 1826298458406912000
author Amin, A
Snow, R
Kokwaro, G
author_facet Amin, A
Snow, R
Kokwaro, G
author_sort Amin, A
collection OXFORD
description BACKGROUND AND OBJECTIVE: Malaria is a disease of major public health importance in Kenya killing 26,000 children under 5 years of age annually. This paper seeks to assess the quality of sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) products available over-the-counter to communities in Kenya as most malaria fevers are self-medicated using drugs from the informal retail sector. METHODS: A retail audit of 880 retail outlets was carried in 2002 in four districts in Kenya, in which antimalarial drug stocks and their primary wholesale sources were noted. In addition, the expiry dates on audited products and the basic storage conditions were recorded on a proforma. The most commonly stocked SP and AQ products were then sampled from the top 10 wholesalers in each district and samples subjected to standard United States Pharmacopoeia (USP) tests of content and dissolution. RESULTS AND DISCUSSION: SP and AQ were the most frequently stocked antimalarial drugs, accounting for approximately 75% of all the antimalarial drugs stocked in the four districts. Of 116 SP and AQ samples analysed, 47 (40.5%) did not meet the USP specifications for content and/or dissolution. Overall, approximately 45.3% of SP and 33.0% of AQ samples were found to be sub-standard. Of the sub-standard SP products, 55.2% were suspensions while 61.1% of the substandard AQ products were tablets. Most SP failures were because of the pyrimethamine component. CONCLUSION: There is a need to strengthen post-marketing surveillance systems to protect patients from being treated with sub-standard and counterfeit antimalarial drugs in Kenya.
first_indexed 2024-03-07T04:47:09Z
format Journal article
id oxford-uuid:d3acb97b-4040-4a85-b1eb-af6d4e8e5686
institution University of Oxford
language English
last_indexed 2024-03-07T04:47:09Z
publishDate 2005
record_format dspace
spelling oxford-uuid:d3acb97b-4040-4a85-b1eb-af6d4e8e56862022-03-27T08:13:02ZThe quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d3acb97b-4040-4a85-b1eb-af6d4e8e5686EnglishSymplectic Elements at Oxford2005Amin, ASnow, RKokwaro, G BACKGROUND AND OBJECTIVE: Malaria is a disease of major public health importance in Kenya killing 26,000 children under 5 years of age annually. This paper seeks to assess the quality of sulphadoxine-pyrimethamine (SP) and amodiaquine (AQ) products available over-the-counter to communities in Kenya as most malaria fevers are self-medicated using drugs from the informal retail sector. METHODS: A retail audit of 880 retail outlets was carried in 2002 in four districts in Kenya, in which antimalarial drug stocks and their primary wholesale sources were noted. In addition, the expiry dates on audited products and the basic storage conditions were recorded on a proforma. The most commonly stocked SP and AQ products were then sampled from the top 10 wholesalers in each district and samples subjected to standard United States Pharmacopoeia (USP) tests of content and dissolution. RESULTS AND DISCUSSION: SP and AQ were the most frequently stocked antimalarial drugs, accounting for approximately 75% of all the antimalarial drugs stocked in the four districts. Of 116 SP and AQ samples analysed, 47 (40.5%) did not meet the USP specifications for content and/or dissolution. Overall, approximately 45.3% of SP and 33.0% of AQ samples were found to be sub-standard. Of the sub-standard SP products, 55.2% were suspensions while 61.1% of the substandard AQ products were tablets. Most SP failures were because of the pyrimethamine component. CONCLUSION: There is a need to strengthen post-marketing surveillance systems to protect patients from being treated with sub-standard and counterfeit antimalarial drugs in Kenya.
spellingShingle Amin, A
Snow, R
Kokwaro, G
The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector.
title The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector.
title_full The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector.
title_fullStr The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector.
title_full_unstemmed The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector.
title_short The quality of sulphadoxine-pyrimethamine and amodiaquine products in the Kenyan retail sector.
title_sort quality of sulphadoxine pyrimethamine and amodiaquine products in the kenyan retail sector
work_keys_str_mv AT amina thequalityofsulphadoxinepyrimethamineandamodiaquineproductsinthekenyanretailsector
AT snowr thequalityofsulphadoxinepyrimethamineandamodiaquineproductsinthekenyanretailsector
AT kokwarog thequalityofsulphadoxinepyrimethamineandamodiaquineproductsinthekenyanretailsector
AT amina qualityofsulphadoxinepyrimethamineandamodiaquineproductsinthekenyanretailsector
AT snowr qualityofsulphadoxinepyrimethamineandamodiaquineproductsinthekenyanretailsector
AT kokwarog qualityofsulphadoxinepyrimethamineandamodiaquineproductsinthekenyanretailsector